Abstract
Background:
To evaluate cause-specific mortality following radical prostatectomy (RP) in a population cohort of US men adjusting for competing risks.
Methods:
The Surveillance, Epidemiology and End Results (SEER) database was used to identify 120 392 men undergoing RP for clinically localized prostate cancer between 1988 and 2003. Cause-specific mortality data were extracted through 2006 and cumulative incidence was estimated using a competing risks approach.
Results:
The stage distribution of the cancers was 32% local, 28% regional, 40% unknown, and 80% of tumors Gleason ⩽7. Median follow-up was 7 years. The 15-year prostate cancer-specific mortality was 5.3% and the non-prostate cancer mortality was 30.6%. Stage, grade and race had minimal impact on non-prostate cancer mortality. At 15 years following surgery, mortality due to cardiovascular diseases was 11%, other cancers 9.1%, and other causes 10.5%. Among men ⩾65 years, 15-year cancer-specific mortality was 6% and non-prostate cancer mortality was 40.8%.
Conclusions:
Following RP, death from cardiovascular diseases, other cancers, and other causes is far more common than death from prostate cancer. In men diagnosed with prostate cancer, significant efforts should be made to prevent, diagnose, and treat these diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer Statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.
Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869–875.
Satariano WA, Ragland KE, Van Den Eeden SK . Cause of death in men diagnosed with prostate carcinoma. Cancer 1998; 83: 1180–1188.
Newschaffer CJ, Otani K, McDonald MK, Penberthy LT . Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Nat Cancer Inst 2000; 92: 613–621.
Cancer Statistics Datasets & Software Publications Information for Cancer Registrars, Homepage. http://www.seer.cancer.gov/.
Surveillance Research Program, NCI. Cancer Statistics Datasets & Software Publications Information for Cancer Registrars. http://www.seer.cancer.gov/codrecode/1969+_d09172004/index.html.
Surveillance Research Program, NCI. SEER Program: Camparative Staging Guide for Cancer. http://www.seer.cancer.gov/manuals/historic/comp_stage1.1pdf.
Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.
Kim HT . Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13: 559–565.
Marubini E, M GV . Analysing Survival Data from Clinical Trials and Observational Studies. Wiley: Chichester, 1995.
Blanchard CM, Courneya KS, Stein K . Cancer survivors′ adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society′s SCS-II. J Clin Onc 2008; 26: 2198–2204.
Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden Follow-up Study. J Nat Cancer Inst 2010; 102: 950–958.
Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J . 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 2007; 177: 932–936.
Dignam JJ, Kocherginsky MN . Choice and interpretation of statistical tests used when competing risks are present. J Clin Onc 2008; 26: 4027–4034.
Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur Urol 2011; 59: 88–95.
Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, Nordling S et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Nat Cancer Inst 2008; 100: 1144–1154.
Keating NL, O’Malley AJ, Smith MR . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Onc 2006; 24: 4448–4456.
Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493–1500.
Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL . Determining cause of death in prostate cancer: Are death certificates valid? J Nat Cancer Inst 2001; 93: 1822–1823.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Appendix A
Appendix A
SEER codes used for cause of death definition
Prostate cancer: 28010
Cardiovascular diseases: 50060, 50070, 50080, 50090, 50100, 50110
Other cancers: 20010, 20020, 20030, 20040, 20050, 20060, 20070, 20080, 20090, 20100, 21010, 21020, 21030, 21040, 21050, 21060, 21071, 21072, 21080, 21090, 21100, 2110, 21120, 21130, 22010, 22020, 22030, 22040, 22050, 22060, 23000, 24000, 25010, 25020, 26000, 27010, 27020, 27030, 27040, 27050, 27060, 27070, 28020, 28030, 28040, 29010, 29020, 29030, 29040, 30000, 31010, 32010, 32020, 33010, 33040, 34000, 35011, 35012, 35013, 35021, 35031, 35022, 35023, 35041, 35043, 36010, 36020, 37000
Other causes: 38000, 50000, 50010, 50030, 50040, 50050, 50051, 50120, 50130, 50140, 50150, 50160, 50170, 50180, 50190, 50200, 50210, 50220, 50230, 50300
Rights and permissions
About this article
Cite this article
Shikanov, S., Kocherginsky, M., Shalhav, A. et al. Cause-specific mortality following radical prostatectomy. Prostate Cancer Prostatic Dis 15, 106–110 (2012). https://doi.org/10.1038/pcan.2011.55
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2011.55
Keywords
This article is cited by
-
Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience
Cardio-Oncology (2023)
-
Cardiovascular disease prevention and management of pre-existent cardiovascular disease in a cohort of prostate cancer survivors
Journal of Cancer Survivorship (2023)
-
Healthcare fragmentation and cardiovascular risk control among older cancer survivors in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study
Journal of Cancer Survivorship (2021)
-
Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients
European Radiology (2021)
-
Die Rolle der PSMA-PET-CT in der Diagnostik und Therapie des Prostatakarzinoms
Urologie in der Praxis (2020)